

Cover Story
Guest Editorial
Over and over again, I’ve seen the same missteps, clumsy excuses, and faulty logic during sponsor presentations to the FDA Oncologic Drugs Advisory Committee, repeated as if part of a tragic, regulatory update to the movie Groundhog Day.
In Brief


Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- Gonzalez-Angulo Found Guilty In MD Anderson Poisoning Case
- NCI slated to get a $9 million raise as Trump’s budget proposes about 10% cut for NIH
- FDA issues warning letter to ImmunityBio over misleading claims about cancer drug














